Processa Pharmaceuticals Inc has a consensus price target of $3.8, established from looking at the 10 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Benchmark on May 13, 2024, April 25, 2024, and March 6, 2024. With an average price target of $6.67 between HC Wainwright & Co., HC Wainwright & Co., and Benchmark, there's an implied 296.83% upside for Processa Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/13/2024 | Buy Now | 376.19% | HC Wainwright & Co. | Raghuram Selvaraju | → $8 | Reiterates | Buy → Buy | Get Alert |
04/25/2024 | Buy Now | 376.19% | HC Wainwright & Co. | Raghuram Selvaraju | → $8 | Initiates | → Buy | Get Alert |
03/06/2024 | Buy Now | 138.1% | Benchmark | Robert Wasserman | → $4 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
11/17/2023 | Buy Now | — | Maxim Group | Naz Rahman | — | Downgrade | Buy → Hold | Get Alert |
04/04/2023 | Buy Now | 138.1% | Benchmark | Aydin Huseynov | $180 → $80 | Maintains | Speculative Buy | Get Alert |
04/03/2023 | Buy Now | 78.57% | Oppenheimer | Francois Brisebois | $100 → $60 | Maintains | Outperform | Get Alert |
01/12/2023 | Buy Now | 197.62% | Maxim Group | Naz Rahman | $180 → $100 | Maintains | Buy | Get Alert |
04/19/2022 | Buy Now | 435.71% | Maxim Group | Naz Rahman | → $180 | Initiates | → Buy | Get Alert |
08/03/2021 | Buy Now | 1090.48% | Oppenheimer | Francois Brisebois | → $400 | Initiates | → Outperform | Get Alert |
08/02/2021 | Buy Now | 1090.48% | Oppenheimer | Francois Brisebois | → $400 | Initiates | → Outperform | Get Alert |
The latest price target for Processa Pharma (NASDAQ: PCSA) was reported by HC Wainwright & Co. on May 13, 2024. The analyst firm set a price target for $8.00 expecting PCSA to rise to within 12 months (a possible 376.19% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for Processa Pharma (NASDAQ: PCSA) was provided by HC Wainwright & Co., and Processa Pharma reiterated their buy rating.
There is no last upgrade for Processa Pharma.
The last downgrade for Processa Pharmaceuticals Inc happened on November 17, 2023 when Maxim Group changed their price target from N/A to N/A for Processa Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Processa Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Processa Pharma was filed on May 13, 2024 so you should expect the next rating to be made available sometime around May 13, 2025.
While ratings are subjective and will change, the latest Processa Pharma (PCSA) rating was a reiterated with a price target of $8.00 to $8.00. The current price Processa Pharma (PCSA) is trading at is $1.68, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.